Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary
December 16 2021 - 8:00AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing meaningful
innovations in immuno-dermatology, today announced the appointment
of Mas Matsuda, Esq. as General Counsel and Corporate Secretary.
Mr. Matsuda joins Arcutis from Halozyme Therapeutics Inc. and
succeeds Keith Klein, Esq. who announced his retirement after a
successful 30-year industry career. In this role, Mr. Matsuda will
oversee all legal and compliance matters for the Company.
“On behalf of our entire team, we’d like to thank Keith for his
considerable contributions to our efforts in establishing Arcutis
as a leading medical dermatology company. He has been an invaluable
advisor and partner to me during his tenure,” said Frank Watanabe,
President and CEO of Arcutis.
Watanabe added, “Mas brings substantial corporate and commercial
legal experience within biotechnology, which will be instrumental
as we focus on the growth of Arcutis and the potential approval and
ultimate commercialization of a diverse pipeline of topical
therapies for immune-mediated skin diseases.”
“I am thrilled to be joining Arcutis at this exciting time as we
prepare for a potential approval and launch of topical roflumilast
cream in psoriasis, and advance pivotal studies across multiple
dermatological conditions,” said Mas Matsuda. “I look forward to
joining this dynamic and experienced team as we deliver on the
promise of bringing meaningful innovation for millions of patients
with serious skin diseases.”
Mr. Matsuda brings over 20 years of legal experience, including
corporate law, compliance, commercial law, employment, and mergers
and acquisitions. Previously, he was Senior Vice President, General
Counsel, Chief Compliance Officer and Corporate Secretary at
Halozyme Therapeutics, Inc. Prior to Halozyme, Mr. Matsuda worked
at Amgen for 18 years in positions of increasing responsibility
with his last role serving as Vice President, Law, Global
Commercial Operations at Amgen, where he was responsible for
strategic commercial legal support to the U.S. Commercial
Operations organization, as well as Medical Affairs, Compliance,
Global Value, Access & Policy, Global Marketing and Biosimilars
division. Mr. Matsuda received his B.S. in Business Administration
with a dual emphasis in Corporate Finance and International Finance
from the University of Southern California, and his J.D. from
University of California, Hastings College of the Law.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a medical dermatology company that champions
meaningful innovation to address the urgent needs of patients
living with immune-mediated dermatological diseases and conditions.
With a commitment to solving the most persistent patient challenges
in dermatology, Arcutis harnesses our unique dermatology
development platform coupled with our dermatology expertise to
build differentiated therapies against biologically validated
targets. Arcutis’ dermatology development platform includes a
robust pipeline with multiple clinical programs for a range of
inflammatory dermatological conditions, with one NDA submitted to
the FDA and three Phase 3 clinical data readouts anticipated by the
end of 2022. The company’s lead program, topical roflumilast, has
the potential to advance the standard of care for plaque psoriasis,
atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For
more information, visit www.arcutis.com or follow Arcutis
on LinkedIn and Twitter.
Forward-Looking StatementsThis press release
contains "forward-looking" statements, including, among others,
statements regarding the potential for roflumilast to be approved
for the treatment of adults and adolescents with plaque psoriasis,
and the potential for roflumilast to advance the standard of care
in plaque psoriasis and other inflammatory dermatological
conditions. These statements involve substantial known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance, or achievements to be
materially different from the information expressed or implied by
these forward-looking statements and you should not place undue
reliance on our forward-looking statements. Risks and uncertainties
that may cause our actual results to differ include risks inherent
in the clinical development process and regulatory approval
process, the timing of regulatory filings, and our ability to
defend our intellectual property. For a further description of the
risks and uncertainties applicable to our business, see the "Risk
Factors" section of our Form 10-K filed with U.S. Securities and
Exchange Commission (SEC) on February 16, 2021, as well as our
subsequent filings with the SEC. We undertake no obligation to
revise or update information herein to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts:MediaAmanda Sheldon,
Head of Corporate Communicationsasheldon@arcutis.com
InvestorsEric McIntyre, Head of Investor
Relationsemcintyre@arcutis.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b2384871-f81d-4a6a-b735-dd8f73b6fa09
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024